AbbVie Investors Look For Stabilizing Botox Revenues In Q3 Financials

 
• By Joseph Haas

Reporting its first full quarter of financials since merging with Allergan, AbbVie will be scrutinized for whether its optimistic talk of a quick Botox rebound actually happened.

Business growth
AbbVie's investors want to see if Q2 optimism about Botox proved true

More from Earnings

More from Business